K22.70 Insurance Policy Changes

ICD-10 K22.70 is officially defined as "Barrett's esophagus without dysplasia." code K22.70 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code K22.70 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Feb 19, 2026Medium impact
Photodynamic Therapy for Malignant Disease 8.01.06
Excellus medical policy 8.01.06 covers photodynamic therapy (PDT) for malignant disease. PDT with Photofrin is considered medically appropriate for early-stage non-small-cell lung cancer in patients who are ineligible for surgery and radiation, for completely or partially obstructing endobronchial lesions, for palliative treatment of obstructing esophageal cancer, for Barrett's high-grade dysplasia in patients at high risk during prophylactic esophagectomy who decide on this treatment through shared decision-making, and for palliative treatment of unresectable cholangiocarcinoma as an adjunct to stenting. PDT with 5-aminolevulinic acid is considered medically appropriate for superficial and nodular basal cell skin cancer and for Bowen's disease, only when surgery or radiation is contraindicated, and PDT is considered investigational for other malignancies. The current effective date is February 19, 2026, and the April 28, 2026 edit corrected grammatical errors and alphabetized reference entries.
Aetna · Identified Oct 31, 2026Medium impact
Barrett's Esophagus (CPB 0728, reviewed 2026-10-26)
Aetna's Clinical Policy Bulletin 0728 on Barrett's esophagus (reviewed 2026-10-26) considers radiofrequency ablation medically necessary for members with low-grade dysplasia confirmed by histology from 2 or more endoscopies 3 or more months apart. For members with high-grade dysplasia by biopsy, it considers endoscopic mucosal resection, esophagectomy, fundoplication, photodynamic therapy and radiofrequency ablation medically necessary, and it considers argon plasma coagulation, cryotherapy, laser therapy and several other listed interventions and tests experimental, investigational, or unproven because their effectiveness has not been established.
Aetna · Identified Oct 17, 2026Medium impact
Esophageal and Airway pH Monitoring (CPB 0667, reviewed 2026-10-07)
Aetna Clinical Policy Bulletin 0667 on esophageal and airway pH monitoring, reviewed 2026-10-07, considers esophageal pH monitoring medically necessary for listed indications, such as refractory reflux in members with chest pain after cardiac evaluation, and for evaluating vomiting in infants up to 3 months of age. The policy considers multi-channel intraluminal impedance testing medically necessary for certain reflux and dysphagia indications, and considers airway pH monitoring, pharyngeal pH monitoring and airway impedance measurement experimental, investigational or unproven. This is an older source dated 2026-10-07, which is historical material, and it states no effective date.
Aetna · Identified Aug 18, 2026Medium impact
Upper Gastrointestinal Endoscopy and Gastrointestinal Biopsy (CPB 0738, reviewed 2025-10-29)
Upper gastrointestinal endoscopy (EGD) and GI biopsy are considered medically necessary when the listed criteria are met. Covered high-risk screening includes persons with chronic GERD of 5 years or more who are at risk for Barrett's esophagus, symptomatic pernicious anemia, and cirrhosis with portal hypertension and no prior variceal hemorrhage, and the policy also lists covered diagnostic, therapeutic and sequential or periodic surveillance indications. Routine screening EGD, EGD before bariatric surgery in asymptomatic persons, repeat EGD after a prior normal EGD when symptoms remain unchanged, and EGD for symptoms considered functional in origin are listed as experimental, investigational, or unproven. This is the full policy text is labeled as reviewed 2025-10-29 and includes no change note, and its policy history shows an original effective date of 11/09/2007.
Aetna · Identified Aug 12, 2026Medium impact
Barrett's Esophagus (CPB 0728, reviewed 2025-11-25)
Aetna considers radiofrequency ablation medically necessary for Barrett's esophagus with low-grade dysplasia confirmed by histology on 2 or more endoscopies performed 3 or more months apart. For Barrett's esophagus with high-grade dysplasia by biopsy, endoscopic mucosal resection, esophagectomy, fundoplication, photodynamic therapy and radiofrequency ablation are considered medically necessary. Argon plasma coagulation, cryotherapy or cryoablation, laser therapy, chemoradiation therapy, gastrectomy, multi-polar electro-coagulation and ultrasonic therapy are considered experimental, investigational or unproven for Barrett's esophagus.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
Radiofrequency ablation (RFA) for Barrett esophagus may be considered medically necessary for treatment of high-grade dysplasia. RFA may also be considered medically necessary for low-grade dysplasia when the initial diagnosis is confirmed by 2 pathologists. RFA for Barrett esophagus when those criteria are not met, including Barrett esophagus without dysplasia, is considered investigational, and cryoablation for Barrett esophagus is considered investigational with or without dysplasia. The 05/06/2026 policy history entry states that the policy statements were unchanged and that one ICD-9 diagnosis code was removed from the Code Reference section.

Watch K22.70

Get one email when a payer policy names K22.70, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code K22.70?

There are 6 tracked policy changes affecting code K22.70, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code K22.70?

Payers that have issued tracked updates for code K22.70 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code K22.70 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code K22.70. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code K22.70?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Photodynamic Therapy for Malignant Disease 8.01.06

Barrett's Esophagus (CPB 0728, reviewed 2026-10-26)

Esophageal and Airway pH Monitoring (CPB 0667, reviewed 2026-10-07)

Upper Gastrointestinal Endoscopy and Gastrointestinal Biopsy (CPB 0738, reviewed 2025-10-29)

Barrett's Esophagus (CPB 0728, reviewed 2025-11-25)

Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus

What insurance policy changes affect code K22.70?

Which payers have updated policy for code K22.70?

How do I get notified when code K22.70 policy changes?

Why do payers change policies for code K22.70?